179 related articles for article (PubMed ID: 31285359)
1. Model-based evaluation of the long-term cost-effectiveness of systematic case-finding for COPD in primary care.
Lambe T; Adab P; Jordan RE; Sitch A; Enocson A; Jolly K; Marsh J; Riley R; Miller M; Cooper BG; Turner AM; Ayres JG; Stockley R; Greenfield S; Siebert S; Daley A; Cheng KK; Fitzmaurice D; Jowett S
Thorax; 2019 Aug; 74(8):730-739. PubMed ID: 31285359
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of physical activity in the management of COPD patients in the UK.
Ramos M; Lamotte M; Gerlier L; Svangren P; Miquel-Cases A; Haughney J
Int J Chron Obstruct Pulmon Dis; 2019; 14():227-239. PubMed ID: 30697043
[TBL] [Abstract][Full Text] [Related]
3. Targeted case finding for chronic obstructive pulmonary disease versus routine practice in primary care (TargetCOPD): a cluster-randomised controlled trial.
Jordan RE; Adab P; Sitch A; Enocson A; Blissett D; Jowett S; Marsh J; Riley RD; Miller MR; Cooper BG; Turner AM; Jolly K; Ayres JG; Haroon S; Stockley R; Greenfield S; Siebert S; Daley AJ; Cheng KK; Fitzmaurice D
Lancet Respir Med; 2016 Sep; 4(9):720-730. PubMed ID: 27444687
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis.
Hertel N; Kotchie RW; Samyshkin Y; Radford M; Humphreys S; Jameson K
Int J Chron Obstruct Pulmon Dis; 2012; 7():183-99. PubMed ID: 22500119
[TBL] [Abstract][Full Text] [Related]
5. TargetCOPD: a pragmatic randomised controlled trial of targeted case finding for COPD versus routine practice in primary care: protocol.
Jordan RE; Adab P; Jowett S; Marsh JL; Riley RD; Enocson A; Miller MR; Cooper BG; Turner AM; Ayres JG; Cheng KK; Jolly K; Stockley RA; Greenfield S; Siebert S; Daley A; Fitzmaurice DA
BMC Pulm Med; 2014 Oct; 14():157. PubMed ID: 25280869
[TBL] [Abstract][Full Text] [Related]
6. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease.
Spencer M; Briggs AH; Grossman RF; Rance L
Pharmacoeconomics; 2005; 23(6):619-37. PubMed ID: 15960557
[TBL] [Abstract][Full Text] [Related]
7. The cost-effectiveness of testing for hepatitis C in former injecting drug users.
Castelnuovo E; Thompson-Coon J; Pitt M; Cramp M; Siebert U; Price A; Stein K
Health Technol Assess; 2006 Sep; 10(32):iii-iv, ix-xii, 1-93. PubMed ID: 16948891
[TBL] [Abstract][Full Text] [Related]
8. A randomised controlled equivalence trial to determine the effectiveness and cost-utility of manual chest physiotherapy techniques in the management of exacerbations of chronic obstructive pulmonary disease (MATREX).
Cross J; Elender F; Barton G; Clark A; Shepstone L; Blyth A; Bachmann M; Harvey I;
Health Technol Assess; 2010 May; 14(23):1-147, iii-iv. PubMed ID: 20487638
[TBL] [Abstract][Full Text] [Related]
9. Systematic review and modelling of the cost-effectiveness of cardiac magnetic resonance imaging compared with current existing testing pathways in ischaemic cardiomyopathy.
Campbell F; Thokala P; Uttley LC; Sutton A; Sutton AJ; Al-Mohammad A; Thomas SM
Health Technol Assess; 2014 Sep; 18(59):1-120. PubMed ID: 25265259
[TBL] [Abstract][Full Text] [Related]
10. Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat® fixed-dose combination for chronic obstructive pulmonary disease patients in Italy.
Selya-Hammer C; Gonzalez-Rojas Guix N; Baldwin M; Ternouth A; Miravitlles M; Rutten-van Mölken M; Goosens LM; Buyukkaramikli N; Acciai V
Ther Adv Respir Dis; 2016 Oct; 10(5):391-401. PubMed ID: 27405723
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of Pulmonary Rehabilitation Among US Adults With Chronic Obstructive Pulmonary Disease.
Mosher CL; Nanna MG; Jawitz OK; Raman V; Farrow NE; Aleem S; Casaburi R; MacIntyre NR; Palmer SM; Myers ER
JAMA Netw Open; 2022 Jun; 5(6):e2218189. PubMed ID: 35731514
[TBL] [Abstract][Full Text] [Related]
12. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
[TBL] [Abstract][Full Text] [Related]
13. Screening for Asymptomatic Coronary Artery Disease in Waitlisted Kidney Transplant Candidates: A Cost-Utility Analysis.
Ying T; Tran A; Webster AC; Klarenbach SW; Gill J; Chadban S; Morton R
Am J Kidney Dis; 2020 May; 75(5):693-704. PubMed ID: 31810731
[TBL] [Abstract][Full Text] [Related]
14. A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context.
Buxton M; Caine N; Chase D; Connelly D; Grace A; Jackson C; Parkes J; Sharples L
Health Technol Assess; 2006 Aug; 10(27):iii-iv, ix-xi, 1-164. PubMed ID: 16904046
[TBL] [Abstract][Full Text] [Related]
15. SeHCAT [tauroselcholic (selenium-75) acid] for the investigation of bile acid malabsorption and measurement of bile acid pool loss: a systematic review and cost-effectiveness analysis.
Riemsma R; Al M; Corro Ramos I; Deshpande SN; Armstrong N; Lee YC; Ryder S; Noake C; Krol M; Oppe M; Kleijnen J; Severens H
Health Technol Assess; 2013 Dec; 17(61):1-236. PubMed ID: 24351663
[TBL] [Abstract][Full Text] [Related]
16. A UK-based cost-utility analysis of indacaterol, a once-daily maintenance bronchodilator for patients with COPD, using real world evidence on resource use.
Price D; Asukai Y; Ananthapavan J; Malcolm B; Radwan A; Keyzor I
Appl Health Econ Health Policy; 2013 Jun; 11(3):259-74. PubMed ID: 23529714
[TBL] [Abstract][Full Text] [Related]
17. Total hip replacement and surface replacement for the treatment of pain and disability resulting from end-stage arthritis of the hip (review of technology appraisal guidance 2 and 44): systematic review and economic evaluation.
Clarke A; Pulikottil-Jacob R; Grove A; Freeman K; Mistry H; Tsertsvadze A; Connock M; Court R; Kandala NB; Costa M; Suri G; Metcalfe D; Crowther M; Morrow S; Johnson S; Sutcliffe P
Health Technol Assess; 2015 Jan; 19(10):1-668, vii-viii. PubMed ID: 25634033
[TBL] [Abstract][Full Text] [Related]
18. A lifetime Markov model for the economic evaluation of chronic obstructive pulmonary disease.
Menn P; Leidl R; Holle R
Pharmacoeconomics; 2012 Sep; 30(9):825-40. PubMed ID: 22799876
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom.
Samyshkin Y; Kotchie RW; Mörk AC; Briggs AH; Bateman ED
Eur J Health Econ; 2014 Jan; 15(1):69-82. PubMed ID: 23392624
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
